Xarelto Lawsuit Numbers Increase In Philadelphia Mass Tort

March 23, 2016 – – BloodThinnerHelp.com reports on the increased number of cases added to the Philadelphia mass tort for cases involving the blood thinning drug Xarelto. Plaintiffs have alleged that after using Xarelto, manufactured by Johnson & Johnson and Bayer AG, they have suffered negative side effects that they claim were not properly disclosed to them.

A Philadelphia mass tort program was established for those cases filed in Pennsylvania state court as a more efficient way to manage litigation. Those numbers have now reached 680 cases. In addition to the mass tort program the JPML has consolidated all federally-filed into MDL No. 2592 in Eastern Louisiana. Cases in the MDL have reached 2,800.

The drug was first introduced in the United States in 2011 and was approved by the FDA for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, atrial fibrillation, and for general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. When released to the market no known reversal agent for the drug existed and many patients who have used Xarelto reported side effects such as internal bleeding or anemia. Other reported injuries included gastrointestinal bleeding, brain hemorrhages, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke, and heart attacks.

Xarelto has not yet been recalled but the FDA has issued several important safety communications regarding Xarelto as well as two “black box warnings.” Also known as a “boxed warning,” a “black box warning” is the strictest warning that can be issued by the FDA for a drug. It usually refers to the fact that there is “reasonable evidence” that some danger exists in regard to the drug.

The Honorable Judge Eldon E. Fallon is overseeing the litigation and has scheduled the first “bellwether” trial for January 2017. Until then, Attorney Joseph Osborne is working with those affected negatively by the drug. Those individuals will have the opportunity to explore their legal options and may be entitled to significant compensation. Osborne is now offering free legal consultation for those affected.

To request additional information or ask questions, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008822